Table 1 Studies with anti-HER2 molcules plus hormonal therapy in the first-line metastaic breast cancer

Kaufman et al. 2009 (TANDEM study)

207

Anastrozole 1 mg po daily + T iv (4 mg/kg loading dose, then 2 mg/kg weekly)

4.8

28.5

21

Anastrozole 1 mg po daily

2.4 (p = 0.002)

23.9 (p = 0.325)

7 (p = 0.018)

Huober et al. 2012 (ELECTRA)

92

Letrozole 2.5 mg po daily + T iv (4 mg/kg loading dose, then 2 mg/kg weekly)

14.1

NR

27

Letrozole 2.5 mg po daily

3.3 (p = 0.23)

NR

13 (p = 0.002)

Johnston et al. 2009 (EGF30008)

263

Letrozole 2.5 mg po + Lapatinib 1500 mg po daily

8.2

33.3

28

Letrozole 2.5 mg po + placebo po daily

3.0 (p = 0.019)

32.3 (p = 0.113)

15 (p = 0.021)